917357-85-8 Usage
Uses
Used in Chemical Synthesis:
(R)-3-[(2-Hydroxy-ethyl)-methyl-amino]-pyrrolidine-1-carboxylic acid benzyl ester is used as a building block in the chemical synthesis industry for the creation of more complex molecules and compounds. Its unique structure and chirality make it a valuable component in the development of novel pharmaceuticals and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (R)-3-[(2-Hydroxy-ethyl)-methyl-amino]-pyrrolidine-1-carboxylic acid benzyl ester is used as a key intermediate in the development of new drugs. Its potential applications may include the treatment of various diseases, depending on the specific compounds synthesized from it. (R)-3-[(2-Hydroxy-ethyl)-methyl-amino]-pyrrolidine-1-carboxylic acid benzyl ester's chirality and functional groups offer opportunities for targeted drug design and optimization.
Used in Drug Delivery Systems:
(R)-3-[(2-Hydroxy-ethyl)-methyl-amino]-pyrrolidine-1-carboxylic acid benzyl ester may also be utilized in the development of drug delivery systems. Its structural features could be exploited to enhance the solubility, stability, or targeted delivery of therapeutic agents, potentially improving their efficacy and reducing side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 917357-85-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,7,3,5 and 7 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 917357-85:
(8*9)+(7*1)+(6*7)+(5*3)+(4*5)+(3*7)+(2*8)+(1*5)=198
198 % 10 = 8
So 917357-85-8 is a valid CAS Registry Number.
917357-85-8Relevant academic research and scientific papers
INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1
-
Page/Page column 29; 30, (2010/11/25)
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salts or solvates thereof, wherein n, X, Y, R1, R2, R3 and R4 are as described in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating conditions that are mediated by the modulation of 11 βHSD1 , the method comprising administering to a mammal an effective amount of a compound of formula (I).
